Volume 30; Issue 2

Nature Biotechnology

Volume 30; Issue 2
1

UK government unveils innovation booster

Year:
2012
Language:
english
File:
PDF, 104 KB
english, 2012
2

Personal medicine—the new banking crisis

Year:
2012
Language:
english
File:
PDF, 553 KB
english, 2012
3

Why genies don't go back into bottles

Year:
2012
Language:
english
File:
PDF, 107 KB
english, 2012
6

Smooth muscle diversity from human pluripotent cells

Year:
2012
Language:
english
File:
PDF, 290 KB
english, 2012
7

TAL effector–DNA structure

Year:
2012
Language:
english
File:
PDF, 93 KB
english, 2012
8

Life Technologies promises $1,000 genome

Year:
2012
Language:
english
File:
PDF, 694 KB
english, 2012
12

Fresh from the biotech pipeline 2011

Year:
2012
Language:
english
File:
PDF, 477 KB
english, 2012
14

Improving glycoconjugate vaccines

Year:
2012
Language:
english
File:
PDF, 93 KB
english, 2012
17

Planning for the exit

Year:
2012
Language:
english
File:
PDF, 216 KB
english, 2012
18

Enbrel patent surfaces

Year:
2012
Language:
english
File:
PDF, 133 KB
english, 2012
19

Funding and performance at the US Patent and Trademark Office

Year:
2012
Language:
english
File:
PDF, 246 KB
english, 2012
20

The blinded buyer

Year:
2012
Language:
english
File:
PDF, 79 KB
english, 2012
21

India's innovation czar

Year:
2012
Language:
english
File:
PDF, 81 KB
english, 2012
22

In this issue

Year:
2012
Language:
english
File:
PDF, 318 KB
english, 2012
24

True colors of genome variation

Year:
2012
Language:
english
File:
PDF, 93 KB
english, 2012
25

Corrigendum: Chinese vaccine developers gain WHO imprimatur

Year:
2012
Language:
english
File:
PDF, 105 KB
english, 2012
26

Gene-based passive antibody protection from HIV

Year:
2012
Language:
english
File:
PDF, 196 KB
english, 2012
27

Corrigendum: FDA panel votes to pull Avastin in breast cancer, again

Year:
2012
Language:
english
File:
PDF, 105 KB
english, 2012
28

Sangamo's lead zinc-finger therapy flops in diabetic neuropathy

Year:
2012
Language:
english
File:
PDF, 240 KB
english, 2012
29

Corrigendum: Industry continues dabbling with open innovation models

Year:
2012
Language:
english
File:
PDF, 105 KB
english, 2012
30

Gilead's $11 billion HCV bet

Year:
2012
Language:
english
File:
PDF, 71 KB
english, 2012
31

Amyloid disease drug approved

Year:
2012
Language:
english
File:
PDF, 135 KB
english, 2012
33

Complex binding sites made to order

Year:
2012
Language:
english
File:
PDF, 420 KB
english, 2012
34

Ablynx drops lead nanobody

Year:
2012
Language:
english
File:
PDF, 81 KB
english, 2012
35

Big pharma upheavals cast shadow across biotech sector

Year:
2012
Language:
english
File:
PDF, 247 KB
english, 2012
36

Mapping chromatin regulators

Year:
2012
Language:
english
File:
PDF, 93 KB
english, 2012
37

People

Year:
2012
Language:
english
File:
PDF, 93 KB
english, 2012
38

OpenVigil—free eyeballs on AERS pharmacovigilance data

Year:
2012
Language:
english
File:
PDF, 179 KB
english, 2012
39

Toll-like receptor blocker slows beta cell death in type 1 diabetes

Year:
2012
Language:
english
File:
PDF, 81 KB
english, 2012
40

Affymetrix sued for fraud

Year:
2012
Language:
english
File:
PDF, 71 KB
english, 2012
41

Recent patent applications related to stem cells

Year:
2012
Language:
english
File:
PDF, 45 KB
english, 2012
42

2011—Big biotechs gorge on debt

Year:
2012
Language:
english
File:
PDF, 246 KB
english, 2012
43

Fourth-quarter biotech job picture

Year:
2012
Language:
english
File:
PDF, 81 KB
english, 2012
44

Around the world in a month

Year:
2012
Language:
english
File:
PDF, 694 KB
english, 2012